Results 21 to 30 of about 8,860 (153)

Correlations between atazanavir C_trough and hyperbilirubinemia: a case report

Journal of Medical Case Reports, 2009
Introduction Hyperbilirubinemia is a common side effect of the antiretroviral agent atazanavir but is generally reversible upon discontinuation of treatment.
Gulminetti Roberto, Novati Stefano, Uglietti Alessia, Maserati Renato   +3 more
doaj   +1 more source

Pharmacogenetic Associations Between Atazanavir/UGT1A1*28 and Efavirenz/rs3745274 (CYP2B6) Account for Specific Adverse Reactions in Chilean Patients Undergoing Antiretroviral Therapy

Frontiers in Pharmacology, 2021
Background: Efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor, and atazanavir (ATV), a protease inhibitor, are drugs widely used in antiretroviral therapy (ART) for people living with HIV.
Daniela Poblete, Fernando Bernal, Gabriel Llull, Sebastian Archiles, Patricia Vasquez, Leonardo Chanqueo, Nicole Soto, María A. Lavanderos, María A. Lavanderos, Luis A. Quiñones, Luis A. Quiñones, Nelson M. Varela, Nelson M. Varela   +12 more
doaj   +1 more source

Population pharmacokinetics of ritonavir-boosted atazanavir in subsequent-line treatment in African children with HIV

Antimicrobial Agents and Chemotherapy
Ritonavir-boosted atazanavir (atazanavir/r) is an effective once-daily option for pediatric subsequent-line antiretroviral therapy when used with two nucleoside reverse transcriptase inhibitors (NRTIs).
Jennie van Dyk, Catriona Waitt, Henry Mugerwa, Lubbe Wiesner, Catherine Orrell, Alasdair Bamford, Diana M. Gibb, Helen M. McIlleron, Angela Colbers, David M. Burger, Paolo Denti, Roeland E. Wasmann   +11 more
doaj   +1 more source

PLANNING AND EVALUATION OF BIOEQUIVALENCE STUDIES OF ATAZANAVIR PRODUCTS

Регуляторные исследования и экспертиза лекарственных средств, 2018
The Government of the Russian Federation approved the State strategy of combating the spread of HIV aimed at prevention of HIV epidemic. One of the goals of the Strategy is to increase the coverage of antiretroviral therapy for people infected with HIV ...
N. E. Uvarova, N. N. Eremenko, G. V. Ramenskaya, D. V. Goryachev   +3 more
doaj   +1 more source

Study of atazanavir-induced hyperbilirubinemia among HIV patients on second-line anti-retroviral therapy

APIK Journal of Internal Medicine, 2020
Introduction: Ritonavir-boosted atazanavir (ATV/r) is the preferred second-line protease inhibitor option for HIV patients as per the NACO guidelines. Atazanavir is a protease inhibitor with several advantages including once-daily dosing, low pill burden,
K Ravi, G N Devamsh, K J Umesh, B C Prashant   +3 more
doaj   +1 more source

Atazanavir Is a Competitive Inhibitor of SARS-CoV-2 M^pro, Impairing Variants Replication In Vitro and In Vivo

Pharmaceuticals, 2021
Atazanavir (ATV) has already been considered as a potential repurposing drug to 2019 coronavirus disease (COVID-19); however, there are controversial reports on its mechanism of action and effectiveness as anti-severe acute respiratory syndrome ...
Otávio Augusto Chaves, Carolina Q. Sacramento, André C. Ferreira, Mayara Mattos, Natalia Fintelman-Rodrigues, Jairo R. Temerozo, Leonardo Vazquez, Douglas Pereira Pinto, Gabriel P. E. da Silveira, Laís Bastos da Fonseca, Heliana Martins Pereira, Aluana Santana Carlos, Joana C. d’Avila, João P. B. Viola, Robson Q. Monteiro, Patrícia T. Bozza, Hugo Caire Castro-Faria-Neto, Thiago Moreno L. Souza   +17 more
doaj   +1 more source

Effects of a switch from tenofovir‐ to abacavir‐based antiretroviral therapy, with or without atazanavir, on renal function

Journal of the International AIDS Society, 2016
Introduction Tenofovir disoproxil fumarate (TDF)–associated renal dysfunction may abate when TDF is replaced with abacavir (ABC). The extent to which the third drug atazanavir contributes to renal dysfunction is unclear.
Silvia A Guillemi, Sean H Ling, Julia S Dahlby, Benita Yip, Wendy Zhang, Mark W Hull, Viviane Dias Lima, Robert S Hogg, Ronald Werb, Julio S Montaner, Marianne Harris   +10 more
doaj   +1 more source

Interactions between Phytochemical Components of Sutherlandia Frutescens and the Antiretroviral, Atazanavir In Vitro: Implications for Absorption and Metabolism

Journal of Pharmacy & Pharmaceutical Sciences, 2012
Purpose. African traditional medicinal plants, such as Sutherlandia frutescens have the potential to interact pharmacokinetically with the protease inhibitor class of antiretrovirals, thereby impacting on their safety and efficacy.
Adrienne C Müller, Srinivas Patnala, Olena Kis, Reina Bendayan, Isadore Kanfer   +4 more
doaj   +1 more source

An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir

BMC Infectious Diseases, 2019
Background The World Health Organisation approved boosted atazanavir as a preferred second line protease inhibitor in 2010. This is as an alternative to the current boosted lopinavir. Atazanavir has a lower genetic barrier than lopinavir. We compared the
Eva Agnes Odongpiny Laker, Maria Sarah Nabaggala, Arvind Kaimal, Damalie Nalwanga, Barbara Castelnuovo, Abdu Musubire, Agnes Kiragga, Mohammed Lamorde, Rosalind Parkes- Ratanshi   +8 more
doaj   +1 more source

In silico Exploration of Interactions Between Potential COVID-19 Antiviral Treatments and the Pore of the hERG Potassium Channel—A Drug Antitarget

Frontiers in Cardiovascular Medicine, 2021
Background: In the absence of SARS-CoV-2 specific antiviral treatments, various repurposed pharmaceutical approaches are under investigation for the treatment of COVID-19.
Ehab Al-Moubarak, Mohsen Sharifi, Jules C. Hancox   +2 more
doaj   +1 more source